Aim Immunotech INC. (AIM) — 10-Q Filings

10-Q Filings (6)

• AIM ImmunoTech Narrows Losses Amid Revenue Dip, Delisting Scare — Nov 17, 2025 Risk: high
  AIM ImmunoTech Inc. reported a net loss of $3.284 million for the three months ended September 30, 2025, a decrease from the $3.700 million net loss in the same
• AIM ImmunoTech's Financial Woes Deepen Amid Delisting, Cash Burn — Aug 14, 2025 Risk: high
  AIM ImmunoTech Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $6.499 million, compared to $7.653 million for
• AIM ImmunoTech Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  AIM ImmunoTech Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Hemispherx Biopharma Inc., is focused on biological products. Key
• AIM ImmunoTech Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  AIM ImmunoTech Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly known as Hemispherx Biopharma Inc., is involved in
• AIM ImmunoTech Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  AIM ImmunoTech Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations.
• AIM ImmunoTech Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk:
  AIM ImmunoTech Inc. (AIM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. AIM ImmunoTech Inc. filed a 10-Q report for the quarter ended March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX